Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

INTRODUCTION: Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Piette, François, Belmin, Joël, Vincent, Hélène, Schmidt, Nicolas, Pariel, Sylvie, Verny, Marc, Marquis, Caroline, Mely, Jean, Hugonot-Diener, Laurence, Kinet, Jean-Pierre, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226277/
https://www.ncbi.nlm.nih.gov/pubmed/21504563
http://dx.doi.org/10.1186/alzrt75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226277/
https://www.ncbi.nlm.nih.gov/pubmed/21504563
http://dx.doi.org/10.1186/alzrt75

Ejemplares similares